Author + information
- Robert S. Rosenson,
- Ben Taylor,
- Ligong Chen,
- Lisandro Colantonio,
- Allison Ellman,
- Greer Burkholder and
- Paul Muntner
Background: Following the introduction of antiretroviral therapy (ART), HIV-infected (HIV+) individuals are living longer and coronary heart disease (CHD) has become a leading cause of mortality. Statins are considered first-line therapy for CHD prevention among people with HIV. However, many statins have contraindications with ART.
Objectives: We determined the proportion of HIV+ patients taking any and contraindicated statins.
Methods: We conducted a retrospective cohort study of HIV+ adults with commercial health insurance in 2014. Use of statins was defined by a statin fill in the calendar year. Statin fills for types and doses that have major drug interactions with ART therapy were defined as contraindicated.
Results: Among 23,719 HIV+ patients (mean age 49 years, 83% men), 25% (n=5,931) were taking statins. After multivariable adjustment, statin use was more common among older patients, men, those with CHD, hypertension, diabetes, and patients taking Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) and protease inhibitors (Table, left panel). Overall, 8% (n=472) HIV+ patients filled contraindicated statins. Patients with diabetes were more likely, and those taking NRTIs and non-NRTIs were less likely, to be taking a contraindicated statin (Table, right panel).
Conclusions: Despite high CHD risk, most HIV patients are not taking statins. Among those taking statins, many are taking contraindicated types and dosages which may increase the risk for major drug interactions.
Poster Hall, Hall C
Friday, March 17, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Current Issues in Cardiovascular Epidemiology, Disparities, and Safety
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1148-069
- 2017 American College of Cardiology Foundation